P A R T I C I P A T E
ACTIVE STUDIES
Carefully conducted studies are essential for understanding both the potential benefits and potential risks of psychedelic-assisted therapies. At the Cambridge Psychedelic Research Group, we are deeply grateful to everyone who considers taking part in our advisory groups, clinical trials, online surveys, and observational research.
C U R R E N T L Y R E C R U I T I N GEMBRACE STUDY
A Phase 3, randomised, double-blind, placebo-controlled, multi-centre clinical trial testing whether an investigational drug (CYB003), combined with psychological support and continued use of existing antidepressant medication, can reduce symptoms of major depressive disorder (MDD).
-
The investigational drug, called CYB003, is similar to psilocin — the active ingredient found in some species of mushrooms (commonly known as "magic mushrooms"). At certain doses, psychedelic substances like CYB003 can cause temporary changes in perception, mood, and thinking, including altered senses and unusual thoughts.
-
Adults aged 18–85 with a current diagnosis of major depressive disorder (MDD), who have been taking the same antidepressant medication for at least 4 weeks, but continue to experience depressive symptoms.
The study has additional eligibility criteria that will be assessed by the study team during a screening process. For complete eligibility details, please visit the study’s registration page at ClinicalTrials.gov (NCT06793397).
-
Participants will be randomly assigned to one of three groups. All participants will receive two doses of the investigational drug or placebo, approximately three weeks apart, alongside psychological support, while continuing their existing antidepressant medication.
The treatment period lasts approximately 12 weeks. Afterwards, participants will have the option to take part in a long-term extension study evaluating the safety and long-term efficacy of the investigational drug.
Psychological support is provided by a licensed therapist trained in EMBARK, a psychological support model developed for this study. Therapists work with participants during sessions before, during, and after each dose.
-
This study is being conducted at Addenbrooke's Hospital within the Cambridge University Hospitals NHS Foundation Trust (CUH), which is located on the Cambridge Biomedical Campus in Cambridgeshire, England. It is one of approximately 60 study sites across the United Kingdom, the United States, Australia, and continental Europe.
Location: Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, United Kingdom.
Study Coordinators: Emma Tudor (emma.tudor@cpft.nhs.uk) & Codie Fahey (psychedelic@cpft.nhs.uk)
Principal Investigator: Dr Liliana Galindo
Sponsor: Cybin IRL Limited
P L E A S E R E A DBEFORE YOU APPLY
Please read the following information carefully:
Our studies are research, not clinical care. Taking part is not the same as receiving treatment from the NHS or another healthcare provider, and there is no guarantee that participation will improve your health.
Each study has its own eligibility criteria. This may include age, diagnosis, current medications, and other health factors. These criteria are designed to protect participants’ safety and ensure reliable study results.
Participation is always voluntary. You can withdraw from a study at any time, without giving a reason and without affecting your usual care.
If you have urgent concerns about your mental or physical health, please contact your general GP, NHS 111, or emergency services (999). For non-urgent support, Samaritans are available 24 hours a day on 116 123. As a research group, we are not set up to provide emergency or crisis care.
If you don’t see a study that seems suitable, you can still express your interest below and we’ll get in touch when new studies start recruiting. Likewise, if you’re unsure about your eligibility or have questions, feel free to contact us to speak with a member of our team.
Don’t see a suitable study?
our TREATMENT room
NIHR Clinical Research Facility
A dedicated treatment and dosing room at Addenbrooke's Hospital, hosted by the Cambridge University Hospitals NHS Foundation Trust, designed to provide a calm and supportive setting for participants.